The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1

Urologic Oncology: Seminars and Original Investigations

Volumn 36, Issue 10, 2018, Pages 459-468

  Sankin, Alexander ^a   Narasimhulu, Deepa ^a   John, Peter ^a   Gartrell, Benjamin ^a   Schoenberg, Mark ^a   Zang, Xingxing ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H3 LIGAND; CD86 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HHLA2 PROTEIN; IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN; NEW DRUG; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN;

BLADDER CANCER; BLADDER TUMOR; CANCER IMMUNOTHERAPY; DRUG TARGETING; HISTORICAL RESEARCH; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNOGENICITY; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; PROCEDURES; TRANSITIONAL CELL CARCINOMA; TRENDS;

ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; HUMANS; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 85019036423     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2017.04.007     Document Type: Review

References (91)

1. Coley, W.B., The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop Relat Res 262 (1991), 3–11.
2. Pearl, R., Cancer and tuberculosis. Am J Hyg, 9, 1929, 97.
3. Kavoussi, L.R., Brown, E.J., Ritchey, J.K., Ratliff, T.L., Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85 (1990), 62–67.
4. Morales, A., Eidinger, D., Bruce, A.W., Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976), 180–183.
5. Pinsky, C.M., Camacho, F.J., Kerr, D., Geller, N.L., Klein, F.A., Herr, H.A., et al. Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 69 (1985), 47–53.
6. Lamm, D.L., Thor, D.E., Harris, S.C., Reyna, J.A., Stogdill, V.D., Radwin, H.M., Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124 (1980), 38–40.
7. Redelman-Sidi, G., Glickman, M.S., Bochner, B.H., The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol 11 (2014), 153–162.
8. Lamm, D.L., Blumenstein, B.A., David, CrawfordE., Crissman, J.D., Lowe, B.A., Smith, J.A. Jr., et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol 1 (1995), 119–126.
9. Malmstrom, P.U., Wijkstrom, H., Lundholm, C., Wester, K., Busch, C., Norlen, B.J., 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999), 1124–1127.
10. Jarvinen, R., Kaasinen, E., Sankila, A., Rintala, E., FinnBladder, G., Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 56 (2009), 260–265.
11. Duchek, M., Johansson, R., Jahnson, S., Mestad, O., Hellstrom, P., Hellsten, S., et al. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 57 (2010), 25–31.
12. Wu, Y., Enting, D., Rudman, S., Chowdhury, S., Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Rev Anticancer Ther 15 (2015), 509–523.
13. Hanahan, D., Weinberg, RobertA., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
14. Töpfer, K., Kempe, S., Müller, N., Schmitz, M., Bachmann, M., Cartellieri, M., et al. Tumor evasion from T Cell surveillance. J Biomed Biotechnol, 2011, 2011, 19.
15. Bretscher, P.A., A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 96 (1999), 185–190.
16. Zang, X., B7 and CD28 families. Mackay, I., Rose, N., Diamond, B., Davidson, A., (eds.) Encyclopedia of medical immunology, 2014, Springer New York, 174–181.
17. Rudd, C.E., Taylor, A., Schneider, H., CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229 (2009), 12–26.
18. Chinai, J.M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., Zang, X., New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36 (2015), 587–595.
19. Bretscher, P., Cohn, M., A theory of self-nonself discrimination. Science (New York, NY) 169 (1970), 1042–1049.
20. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science (New York, NY) 348 (2015), 124–128.
21. Inman, B.A., Sebo, T.J., Frigola, X., Dong, H., Bergstralh, E.J., Frank, I., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109 (2007), 1499–1505.
22. Boorjian, S.A., Sheinin, Y., Crispen, P.L., Farmer, S.A., Lohse, C.M., Kuntz, S.M., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14 (2008), 4800–4808.
23. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
24. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
25. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
26. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
27. Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
28. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
29. Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
30. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F.L., Carbonnel, F., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13 (2016), 473–486.
31. A Phase 1/2, Open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors.
32. A Phase 1 Study of (Cabozantinib) Plus Nivolumab (CaboNivo) alone or in combination with ipilimumab (CaboNivoIpi) in patients with advanced/metastatic urothelial carcinoma and other genitourinary tumors.
33. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
34. Sharma P. Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: first results from the Phase I/II CheckMate 032 Study. Poster 449. 31st Annual Meeting, Society for Immunotherapy of Cancer; 2016.
35. Chapoval, A.I., Ni, J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2 (2001), 269–274.
36. Zang, X., Loke, P., Kim, J., Murphy, K., Waitz, R., Allison, J.P., B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 100 (2003), 10388–10392.
37. Sica, G.L., Choi, I.H., Zhu, G., Tamada, K., Wang, S.D., Tamura, H., et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18 (2003), 849–861.
38. Prasad, D.V., Richards, S., Mai, X.M., Dong, C., B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18 (2003), 863–873.
39. Zhao, R., Chinai, J.M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H., et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A 110:24 (2013), 9879–9884.
40. Zang, X., Thompson, R.H., Al-Ahmadie, H.A., Serio, A.M., Reuter, V.E., Eastham, J.A., et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104 (2007), 19458–19463.
41. Sun, X., Vale, M., Leung, E., Kanwar, J.R., Gupta, R., Krissansen, G.W., Mouse B7-H3 induces antitumor immunity. Gene Ther 10 (2003), 1728–1734.
42. Prasad, D.V., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., et al. Murine B7-H3 is a negative regulator of T cells. J Immunol 173 (2004), 2500–2506.
43. Tran, C.N., Thacker, S.G., Louie, D.M., Oliver, J., White, P.T., Endres, J.L., et al. Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3. J Immunol 180 (2008), 2989–2998.
44. Suh, W.K., Wang, S.X., Jheon, A.H., Moreno, L., Yoshinaga, S.K., Ganss, B., et al. The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci U S A 101 (2004), 12969–12973.
45. Xu, H., Cheung, I.Y., Guo, H.F., Cheung, N.K., MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69 (2009), 6275–6281.
46. Zang, X., Sullivan, P.S., Soslow, R.A., Waitz, R., Reuter, V.E., Wilton, A., et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23 (2010), 1104–1112.
47. Loos, M., Hedderich, D.M., Ottenhausen, M., Giese, N.A., Laschinger, M., Esposito, I., et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer, 9, 2009, 463.
48. Wu, C.P., Jiang, J.T., Tan, M., Zhu, Y.B., Ji, M., Xu, K.F., et al. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 12 (2006), 457–459.
49. Yamato, I., Sho, M., Nomi, T., Akahori, T., Shimada, K., Hotta, K., et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 101 (2009), 1709–1716.
50. Sun, J., Chen, L.J., Zhang, G.B., Jiang, J.T., Zhu, M., Tan, Y., et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 59 (2010), 1163–1171.
51. Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A., et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 252 (2010), 1044–1051.
52. Sun, Y., Wang, Y., Zhao, J., Gu, M., Giscombe, R., Lefvert, A.K., et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53 (2006), 143–151.
53. Sun, T.W., Gao, Q., Qiu, S.J., Zhou, J., Wang, X.Y., Yi, Y., et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother 61 (2012), 2171–2182.
54. Crispen, P.L., Sheinin, Y., Roth, T.J., Lohse, C.M., Kuntz, S.M., Frigola, X., et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14 (2008), 5150–5157.
55. Xylinas, E., Robinson, B.D., Kluth, L.A., Volkmer, B.G., Hautmann, R., Kufer, R., et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 40 (2014), 121–127.
56. Wu, D., Zhang, Z., Pan, H., Fan, Y., Qu, P., Zhou, J., Upregulation of the B7/CD28 family member B7-H3 in bladder cancer. Oncol Lett 9 (2015), 1420–1424.
57. Loo, D., Alderson, R.F., Chen, F.Z., Huang, L., Zhang, W., Gorlatov, S., et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 18 (2012), 3834–3845.
58. Powderly, J., Cote, G., Flaherty, K., Szmulewitz, R.Z., Ribas, A., Weber, J., et al. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer, 3(Suppl. 2), 2015, O8.
59. Ahmed, M., Cheng, M., Zhao, Q., Goldgur, Y., Cheal, S.M., Guo, H.F., et al. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J Biol Chem 290 (2015), 30018–30029.
60. Luther, N., Cheung, N.K., Souliopoulos, E.P., Karampelas, I., Bassiri, D., Edgar, M.A., et al. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther 9 (2010), 1039–1046.
61. Zhao, X., Zhang, G.B., Gan, W.J., Xiong, F., Li, Z., Zhao, H., et al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett 5 (2013), 805–812.
62. Zhang, W., Wang, J., Wang, Y., Dong, F., Zhu, M., Wan, W., et al. B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells. Oncol Targets Ther 8 (2015), 1721–1733.
63. Podojil, J.R., Liu, L.N., Marshall, S.A., Chiang, M.Y., Goings, G.E., Chen, L., et al. B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. J Autoimmun 44 (2013), 71–81.
64. Kryczek, I., Wei, S., Zou, L., Zhu, G., Mottram, P., Xu, H., et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177 (2006), 40–44.
65. Jeon, H., Ohaegbulam, K.C., Abadi, Y.M., Zang, X., B7x and myeloid-derived suppressor cells in the tumor microenvironment: a tale of two cities. Oncoimmunology, 2, 2013, e24744.
66. Zhu, G., Augustine, M.M., Azuma, T., Luo, L., Yao, S., Anand, S., et al. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 113 (2009), 1759–1767.
67. Tringler, B., Zhuo, S., Pilkington, G., Torkko, K.C., Singh, M., Lucia, M.S., et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11 (2005), 1842–1848.
68. Lee, J.S., Scandiuzzi, L., Ray, A., Wei, J., Hofmeyer, K.A., Abadi, Y.M., et al. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol 189 (2012), 4165–4174.
69. Zhao, L.W., Li, C., Zhang, R.L., Xue, H.G., Zhang, F.X., Zhang, F., et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 116 (2014), 1163–1168.
70. Simon, I., Katsaros, D., Rigault de la, LongraisI., Massobrio, M., Scorilas, A., Kim, N.W., et al. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 106 (2007), 334–341.
71. Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S., Amant, F., Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 63 (2014), 545–557.
72. Krambeck, A.E., Thompson, R.H., Dong, H., Lohse, C.M., Park, E.S., Kuntz, S.M., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 103 (2006), 10391–10396.
73. Qian, Y., Sang, Y., Wang, F.X., Hong, B., Wang, Q., Zhou, X., et al. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases. Oncotarget 7 (2016), 72242–72249.
74. Liu, W.H., Chen, Y.Y., Zhu, S.X., Li, Y.N., Xu, Y.P., Wu, X.J., et al. B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms. Oncol Lett 8 (2014), 2527–2534.
75. Fan, M., Zhuang, Q., Chen, Y., Ding, T., Yao, H., Chen, L., et al. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. Int J Clin Exp Pathol 7 (2014), 6768–6775.
76. Jeon, H., Vigdorovich, V., Garrett-Thomson, S.C., Janakiram, M., Ramagopal, U.A., Abadi, Y.M., et al. Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep 9 (2014), 1089–1098.
77. Dangaj, D., Lanitis, E., Zhao, A., Joshi, S., Cheng, Y., Sandaltzopoulos, R., et al. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res 73 (2013), 4820–4829.
78. Smith, J.B., Lanitis, E., Dangaj, D., Buza, E., Poussin, M., Stashwick, C., et al. Tumor regression and delayed onset toxicity following B7-H4 CAR T cell therapy. Mol Ther 24 (2016), 1987–1999.
79. Zhu, Y., Yao, S., Iliopoulou, B.P., Han, X., Augustine, M.M., Xu, H., et al. B7-H5 costimulates human T cells via CD28H. Nat Commun, 4, 2013, 2043.
80. Janakiram, M., Chinai, J.M., Fineberg, S., Fiser, A., Montagna, C., Medavarapu, R., et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res 21 (2015), 2359–2366.
81. Rahimi, N., Rezazadeh, K., Mahoney, J.E., Hartsough, E., Meyer, R.D., Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis. Mol Biol Cell 23 (2012), 1646–1656.
82. Cheng, H., Janakiram, M., Borczuk, A., Lin, J., Qiu, W., Liu, H., et al. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res 23 (2017), 825–832.
83. Koirala, P., Roth, M.E., Gill, J., Chinai, J.M., Ewart, M.R., Piperdi, S., et al. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep, 6, 2016, 31154.
84. Sankin A, Gartrell B, Cumberbatch K, Stern MP, Huang H, Schoenberg M, et al. New targets for immune checkpoint inhibition in urothelial carcinoma. American Urological Association Annual Meeting, San Diego, CA; 2016.
85. Apolo, A.B., Infante, J.R., Hamid, O., Patel, M.R., Wang, D., Kelly, K., et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: analysis of safety, clinical activity, and PD-L1 expression. J Clin Oncol(Suppl.), 2016, 34 [abstract 4514].
86. Balar, A.V., Galsky, M.D., Loriot, Y., Dawson, N.A., Necchi, A., Srinivas, S., et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1. J Clin Oncol(suppl), 2016, 34 [abstract LBA4500].
87. Sharma, P., Bono, P., Kim, J.W., Spiliopoulou, P., Calvo, E., Pillai, R.N., et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. J Clin Oncol(suppl), 2016, 34 [abstract 4501].
88. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18 (2017), 312–322.
89. Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
90. Plimack, E.R., Bellmunt, J., Gupta, S., Berger, R., Montgomery, R.B., Heath, K., et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol(suppl), 2015, 33 [abstract 4502].
91. Balar A, Bellmunt J, O'Donnell PH, Castellano D, Grivas P, Vuky J, et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. European Society for Medical Oncology Annual Meeting; 2016.